Healthcare

https://techpapersworld.com/wp-content/uploads/2024/11/Successful-first-Aeson®-European-User-Meeting-1280x720.jpg

HealthcareSuccessful first “Aeson® European User Meeting”, marking an important step in the deployment of CARMAT’s artificial heart

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), announces the success of its first “Aeson® European User Meeting”, held on 21 and 22 November 2024 in Chantilly, near Paris. Strong and promising interest in Aeson® from the French and international medical community The forum brought together more than 100 European leaders...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/Caris-Life-Sciences-Showcases-1-1280x720.jpg

HealthcareCaris Life Sciences Showcases Data Demonstrating the Clinical Value of Clonal Hematopoiesis Identification and Subtraction in Liquid Biopsy to Improve the Accuracy of Treatment Recommendations

Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced the presentation of data highlighting the clinical value of subtracting clonal hematopoiesis (CH) mutations from liquid biopsy profiling results to avoid incorrect treatment recommendations. Caris generated the findings, in collaboration with leading cancer centers, including those within the Caris Precision Oncology Alliance™ (Caris POA), and presented the data on November 23, 2024, at the International Society for Liquid Biopsy (ISLB) 6th Annual Congress....

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/Common-Thyroid-Medicine-1280x720.jpg

HealthcareCommon Thyroid Medicine Linked to Bone Loss

Levothyroxine, the second most commonly prescribed medication among older adults in the U.S., may be associated with bone loss, according to a study being presented next week at the annual meeting of the Radiological Society of North America (RSNA). Levothyroxine, marketed under multiple brand names including Synthroid, is a synthetic version of a hormone called thyroxine and is commonly prescribed to treat the condition hypothyroidism, or underactive thyroid. In people with hypothyroidism, the thyroid gland does not produce enough...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/Roche-receives-FDA-approval-for-1280x720.jpg

HealthcareRoche receives FDA approval for first companion diagnostic to identify patients with biliary tract cancer eligible for HER2-targeted treatment with ZIIHERA

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. Food and Drug Administration (FDA) approval of a label expansion into biliary tract cancer (BTC) for the PATHWAY® anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody* test. This test is now the first and only FDA-approved companion diagnostic to aid in the assessment of HER2-positive status to identify BTC patients who are eligible for treatment with Jazz Pharmaceuticals’ ZIIHERA® (zanidatamab-hrii). PATHWAY HER2 (4B5) assay for biliary tract cancer HER2 is a...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/Bioretec-Signed-1-1280x720.jpg

HealthcareBioretec signed a new sales and distribution agreement to accelerate the commercialization of RemeOs™ Trauma Screw in the U.S. civilian hospital market

Bioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopedic implants, is moving ahead with the next phase of the commercialization of its innovative RemeOs™ Trauma Products in the U.S. market. As a continuation to the previously signed logistics agreement with GlobalMed Logistix, Bioretec strengthens now its commercialization efforts by signing a new sales and distribution agreement with Tri-State Biologics (TSB), which is a distributor of medical and surgical products based in New Jersey. TSB is a...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/BioWorld-by-Clarivate-Highlights-1280x720.jpg

HealthcareBioWorld by Clarivate Highlights Gaps in Women’s Health Research and Investment in New Special Series

BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has launched its new special series, ‘Healing the Health Divide.‘ This seven-part series sheds light on the persistent disparities in women’s health research, funding, and treatment. Women make up half of the global population, yet their health remains consistently underserved. Research and treatments have traditionally focused on reproduction and breast health, but these areas represent just a fraction of the broader health challenges women face. From autoimmune...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/New-Report-Lung-Cancer-Survival-Rate-1280x720.jpg

HealthcareNew Report: Lung Cancer Survival Rate Improves, But Gaps in Biomarker Testing and Lack of Screening Hinder Progress

Lung cancer is the leading cause of the cancer deaths in the U.S., but the American Lung Association’s 2024 “State of Lung Cancer” report reveals positive news. The lung cancer survival rate has improved 26% in the last five years. The report also presents opportunities for states to further improve lung cancer survival by increasing access biomarker testing, and for the federal government to work to increase access to screening. The organization’s seventh annual “State of Lung...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/New-Report-from-Clarivate-and-Healthcare-1280x720.jpg

HealthcareNew Report from Clarivate and Healthcare Executive Explores Mainland China’s Biopharma Revolution and Increasing Global Influence

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, in partnership with Healthcare Executive, published by the China Pharmaceutical Enterprises Association, today announced the release of a new report, A Decade of Innovation, A Decade to Come. Over the past decade, Mainland China’s biopharmaceutical sector has rapidly advanced to become a global leader in innovation, ranking among the top three for initial drug launches. Driven by reforms, increased investment, and progressive policies, the industry has reduced approval...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/Law-Offices-of-Jason-Turchin-1-1280x720.jpg

HealthcareLaw Offices of Jason Turchin Represents Victims of Defective Medical Devices

The Law Offices of Jason Turchin is representing victims injured by defective medical devices, including faulty implants, surgical tools, and more. Defective medical devices can lead to severe injuries, long-term health issues, or the need for additional surgeries, leaving victims with mounting medical expenses. “When medical devices fail, the consequences can be devastating,” said Jason Turchin, Esq. “We are committed to helping victims hold manufacturers accountable.” Common Defective Medical Devices: Hip and knee implants Pacemakers Surgical tools Transvaginal mesh Steps to Take...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/11/MarinHealth-Medical-Center-Earns-an-.jpg

HealthcareMarinHealth Medical Center Earns an “A” Hospital Safety Grade from The Leapfrog Group

Today, The Leapfrog Group released its new Hospital Safety Grade report, awarding MarinHealth Medical Center an “A” in acknowledgement of its standards for excellence in patient care and its efforts to protect patients and meet the highest hospital safety standards in the U.S. “This acknowledgment speaks volumes about the care we provide, and even more about the culture of excellence we’ve cultivated at MarinHealth” The Leapfrog Hospital Safety Grade rating system uses stringent criteria to assess hospitals’ safety and quality...

Newer Posts

Older Posts